SAM
HZNP

Silphium Asset Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Silphium Asset Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-200,000
Closed -$23.1M – 73
2023
Q3 		$23.1M Buy
200,000
+35,000
+21% +$3.76M 7.4% 3
2023
Q2 		$17M Buy
165,000
+15,000
+10% +$1.58M 7.37% 2
2023
Q1 		$16.4M Buy
150,000
+10,000
+7% +$1.11M 12.56% 2
2022
Q4 		$15.9M Buy
+140,000
New +$11.6M 15.93% 1

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Silphium Asset Management's HZNP Position: Q4 2023 in Review

Silphium Asset Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 200,000 shares — an estimated $23.1M sold.

Silphium Asset Management first reported a position in HZNP in Q4 2022 and held it in 4 quarters. The position peaked at $23.1M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Silphium Asset Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Silphium Asset Management sold 200,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $23.1M.
  • Silphium Asset Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2022 and held it in 4 quarters.
  • Silphium Asset Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $23.1M in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Silphium Asset Management's 13F filing for Q4 2023, filed 30 Jan 2025.